• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Lifeward Ltd. filed SEC Form 8-K: Other Events

    3/11/26 8:15:41 AM ET
    $LFWD
    Industrial Specialties
    Health Care
    Get the next $LFWD alert in real time by email
    false0001607962L300-00000002 Cabot Rd., Hudson, MAFloor 6Yokneam Ilit+508.251.11544.959.0123Ordinary Shares, par value NIS 0.25NASDAQ00016079622026-03-102026-03-10


    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
    FORM 8-K

    CURRENT REPORT
    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
     
    Date of Report (Date of earliest event reported): March 10, 2026
     
    Lifeward Ltd.

    (Exact Name of Registrant as Specified in its Charter)
      
    Israel
     
    001-36612
     
    Not Applicable
    (State or Other Jurisdiction of Incorporation)
     
    (Commission File Number)
     
    (IRS Employer Identification No.)

    2 Cabot Rd., Hudson, MA
     
    01749
    (Address of principal executive offices)
     
    (Zip Code)
     
    Registrant’s telephone number, including area code: +508.251.1154

    Not applicable
    (Former name or former address, if changed since last report)

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each class
     
    Trading Symbol
     
    Name of each exchange on which registered
    Ordinary Shares, no par value
     
    LFWD
     
    Nasdaq Capital Market

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
     
     
    ☐
    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
     
    ☐
    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
     
    ☐
    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
     
    ☐
    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐
     
    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
     


    Item 8.01          Other Events.

    On March 10, 2026, Lifeward Ltd. (the “Company”) received written notice from the Nasdaq Listing Qualifications Hearings Department of the Nasdaq Stock Market LLC (the “Staff”) stating that the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Requirement”) by maintaining a minimum closing bid price of the Company’s Ordinary Shares of at least $1.00 per share for the last 10 consecutive business days, from February 24, 2026 to March 9, 2026, and that this matter is now closed.
     

    SIGNATURES
     
    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
     
     
    Lifeward Ltd.
     
     
     
    Dated: March 11, 2026
    By:
    /s/ Almog Adar
     
    Name:
    Almog Adar
     
    Title:
    Chief Financial Officer
     

    Get the next $LFWD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LFWD

    DatePrice TargetRatingAnalyst
    2/10/2025$10.00Buy
    Laidlaw
    More analyst ratings

    $LFWD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lifeward Regains Compliance with Nasdaq Minimum Bid Price Requirement

    HUDSON, Mass. and YOKNEAM ILLIT, Israel, March 11, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced it has received a notification letter from The Nasdaq Stock Market LLC ("Nasdaq") confirming that it has regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) ("Rule"). To regain compliance with the Rule, the Company's common stock was required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which the Company satisfied

    3/11/26 8:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

    MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its fourth quarter and full year 2025 financial results before the markets open on Wednesday, March 18, 2026. Mark Grant, President and Chief Executive Officer, and Almog Adar, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-

    3/10/26 4:15:00 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Announces Collaboration With Shirley Ryan AbilityLab to Expand Access for the ReWalk Personal Exoskeleton

    Clinic days offered at Shirley Ryan AbilityLab, the #1 ranked rehabilitation hospital for 35 consecutive years, with the goal of accelerating personal exoskeleton adoption Streamlined pathway from evaluation to real-world use of ReWalk for people living with spinal cord injury (SCI) HUDSON, Mass. and CHICAGO, March 02, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, today announced a joint effort with Shirley Ryan AbilityLab, a global leader in physical medicine and rehabilitation. This collaboration will establish dedicated clinic days launching in

    3/2/26 8:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Turk Joseph E Jr bought $10,140 worth of Ordinary Shares (6,000 units at $1.69), increasing direct ownership by 48% to 18,516 units (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    12/17/24 8:55:09 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Director Swinford Michael bought $43,858 worth of Ordinary Shares (21,622 units at $2.03), increasing direct ownership by 50% to 65,040 units (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    11/27/24 8:03:53 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Director Swinford Michael bought $30,899 worth of Ordinary Shares (16,907 units at $1.83), increasing direct ownership by 64% to 43,418 units (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    11/26/24 7:07:36 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP of Market Access & Strategy Lynch Jeannine was granted 50,000 units of Ordinary Shares, increasing direct ownership by 109% to 96,067 units (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    12/12/25 4:49:11 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    VP of Market Access & Strategy Lynch Jeannine sold $1,018 worth of Ordinary Shares (1,591 units at $0.64) (SEC Form 4)

    4 - Lifeward Ltd. (0001607962) (Issuer)

    9/4/25 5:07:28 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    SEC Form 4 filed by Chief Financial Officer Adar Almog

    4 - Lifeward Ltd. (0001607962) (Issuer)

    8/13/25 5:44:12 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    SEC Filings

    View All

    Lifeward Ltd. filed SEC Form 8-K: Other Events

    8-K - Lifeward Ltd. (0001607962) (Filer)

    3/11/26 8:15:41 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Ltd. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

    8-K - Lifeward Ltd. (0001607962) (Filer)

    3/2/26 4:15:11 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Ltd. filed SEC Form 8-K: Leadership Update

    8-K - Lifeward Ltd. (0001607962) (Filer)

    2/27/26 4:14:36 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Laidlaw initiated coverage on Lifeward with a new price target

    Laidlaw initiated coverage of Lifeward with a rating of Buy and set a new price target of $10.00

    2/10/25 7:00:44 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Leadership Updates

    Live Leadership Updates

    View All

    Lifeward Appoints Bob Marshall as Chairman of the Board

    MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology designed to transform the lives of people with physical limitations or disabilities, announced today that its Board of Directors has appointed Bob Marshall as Chairman of the Board, effective January 1, 2026. He replaces Joseph Turk, who will transition off the Board in connection with his new position at Fresenius Medical Care. "On behalf of the Board and entire Lifeward team, I congratulate Joe on his appointment as Chief Executive Officer of Care Enablement at Fresenius Medical Care, a global leader

    12/19/25 4:05:00 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    MedRhythms Appoints Larry Jasinski as Chief Executive Officer to Lead Next Phase of Growth and Commercial Expansion

    Industry veteran with proven track record in neurorehabilitation and fundraising to lead next phase of growth; Co-founder Brian Harris transitions to Chief Scientific Officer PORTLAND, Maine, July 7, 2025 /PRNewswire/ -- MedRhythms, Inc., a company pioneering the development of next-generation neurotherapeutics to improve walking, mobility and related functional outcomes, and creator of the world's first prescription music platform, announced the appointment of Larry Jasinski as Chief Executive Officer, effective immediately. Co-founder of MedRhythms, Brian Harris, who led the company through product development, successful clinical trials, listing product with the Food and Drug Administrati

    7/7/25 11:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Names Mark Grant as New CEO

    MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, May 19, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that Mark Grant has been appointed as the Company's new President and Chief Executive Officer, effective June 2, 2025. Larry Jasinski, Lifeward's outgoing CEO, will serve as Co-CEO and, as previously announced, will serve in an advisory capacity until the end of June to assist with the transition, and thereafter on an as-needed basis through the end of 2025. "Mark brings 30 years of combined experience in commercia

    5/19/25 8:30:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    $LFWD
    Financials

    Live finance-specific insights

    View All

    Lifeward to Report Fourth Quarter and Full Year 2025 Financial Results on March 18, 2026

    MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its fourth quarter and full year 2025 financial results before the markets open on Wednesday, March 18, 2026. Mark Grant, President and Chief Executive Officer, and Almog Adar, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-

    3/10/26 4:15:00 PM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward Ltd. Reports Third Quarter 2025 Financial Results

    Record quarter of ReWalk systems placed for Medicare beneficiaries since fee schedule established  Ongoing efficiency initiatives drive 16% year-over-year decrease in quarterly cash burn and 27% decrease in quarterly Non-GAAP operating loss Entered into $3.0 million loan agreement with Oramed Ltd. providing additional capital support MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd., (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced its financial results for the three months and nine months ended September 3

    11/14/25 8:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care

    Lifeward to Report Third Quarter Financial Results on November 14, 2025

    MARLBOROUGH, Mass. and YOKNEAM ILLIT, Israel, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Lifeward Ltd. (NASDAQ:LFWD) ("Lifeward" or the "Company"), a global leader in innovative medical technology to transform the lives of people with physical limitations or disabilities, today announced that the Company will release its third quarter 2025 financial results before the markets open on Friday, November 14, 2025. Mark Grant, President and Chief Executive Officer, and Almog Adar, Chief Financial Officer, will host a conference call and live webcast at 8:30 a.m. EST to discuss the financial results. To access the call, analysts and investors may utilize the following: Toll free (U.S.)1-833-316-0561Inte

    11/10/25 7:00:00 AM ET
    $LFWD
    Industrial Specialties
    Health Care